Optimi Health Corp.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Optimi Health Corp. engages in the development and commercialization of psychedelic-assisted therapies and related health products, focusing on the research, formulation, clinical-grade production, and distribution of psychedelic compounds and associated treatment modalities, with emphasis on MDMA-related products and psilocybin extracts for mental health indications. Main products and services - Psychedelic therapeutics development and manufacturing: GMP-grade production of psychedelic compounds designed for clinical and research use; capsule formulations and finished dose forms intended for medical settings. - Psychedelic ingredients and extracts: standardized psilocybin extracts and related active pharmaceutical ingredients for use in research, development, and therapeutic programs. - Clinical support services: treatment protocol development, dosing guidance, regulatory documentation support, and quality assurance activities to facilitate clinical trials and compassionate-use programs. - Research collaborations and partnerships: joint development arrangements with academic and industry partners to advance evidence-based psychedelic therapies; data sharing and joint études to support regulatory submissions. - Analytical testing and quality control: in-house or partnered analytical services to generate COAs, ensure product identity, purity, potency, and contaminant screening in accordance with applicable regulatory standards. - Cannabis testing and ancillary services: laboratory services and testing capabilities for licensed cannabis producers, including stability testing, potency analysis, and microbial testing to support regulated markets. - Related health and wellness products: ancillary offerings aligned with holistic mental health and wellness strategies, including consumer-accessible products that complement clinical therapies where permitted. Latest major company changes - Strategic partnerships and alliances: enters collaborations with research institutions and biotech partners to advance psychedelic therapy programs and expand clinical trial pipelines; these alliances broaden development capabilities and regulatory familiarity across jurisdictions. - Funding and capital activities: secures financing rounds to support expansion of manufacturing, R&D, and regulatory compliance activities; funding rounds enable scale-up of production capabilities and expanded geographic reach. - Product and service launches: launches new GMP-grade psychedelic product lines and expanded psilocybin extract portfolio; broadens treatment modalities and dosing options for clinical use. - Corporate and organizational changes: undergoes corporate restructuring to align operations with regulation-driven growth in psychedelic therapies; adjusts organizational footprint to support increased manufacturing, QA, and clinical collaboration activities. - Operational expansion: expands geographic footprint and manufacturing capacity to support rising demand in North America and select international markets; enhances supply chain and distribution capabilities for regulatory-compliant products. Additional context - Industry and segments: operates in the psychedelic medicines sector with involvement in clinical development, manufacturing, and testing services; ancillary cannabis testing services position the company in adjacent regulated markets. - Target markets and customers: targets healthcare providers, clinical researchers, contract research organizations, licensed pharmaceutical distributors, and regulated cannabis producers; serves government- and university-affiliated research programs where applicable. - Geographic operations: primary operations in Canada, with regulatory activity and market presence in North America and potential expansion into other regulatory jurisdictions as approvals advance. - Founding year and headquarters: founded in 2020; headquarters located in Canada (Franco-European business operations in Frankfurt am Main as a reference for local professional activity, though headquarters remain in Canada per public disclosures). - Subsidiaries and parent relations: maintains subsidiary structures to support manufacturing, testing, and research activities; operates within a corporate group framework to facilitate regulatory compliance and cross-border collaboration. Notes - The company’s product scope centers on regulated psychedelic therapies, with emphasis on MDMA capsules and psilocybin extracts, produced under quality standards suitable for clinical use; the firm also offers testing and analytical services and pursues partnerships to advance its clinical and R&D programs. - While markets and regulatory landscapes evolve, Optimi Health maintains a focus on building a robust pipeline of therapeutic products and services, aligned with rising investor and patient interest in psychedelic-assisted treatment modalities.
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting